Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

5.1K
5.1K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

467
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
467

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Japanese Encephalitis With a Characteristic Neuropathological Distribution Following Early MRI-Based Diagnosis: An Autopsy Case.

Neuropathology : official journal of the Japanese Society of Neuropathology·2026
Same author

Reverse Left Ventricular Remodeling in a Patient With Concurrent Wild-Type Transthyretin Cardiac Amyloidosis and Heart Failure With Reduced Ejection Fraction: The Role of Conventional Heart Failure Therapy.

Cureus·2026
Same author

In memoriam: Shukuro Araki, MD, PhD (1927-2025) pioneer of Japanese neurology and a global leader in familial amyloid polyneuropathy.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis·2026
Same author

Cleidocranial dysplasia caused by a novel de novo RUNX2 splice-site variant.

Human genome variation·2026
Same author

Idiopathic Multicentric Castleman Disease Presenting as Recurrent Acute-Onset Demyelinating Neuropathy.

Internal medicine (Tokyo, Japan)·2026
Same author

Clinical Practice and Diagnostic Trends in Hereditary Transthyretin Amyloidosis: A 25-Year Observational Study.

Medicina (Kaunas, Lithuania)·2026
Same journal

[Neuropathological Autopsies in Japan: Current Scenario and Challenges].

Brain and nerve = Shinkei kenkyu no shinpo·2026
Same journal

[Telemedicine and Digital Technologies in Neurological Intractable Diseases].

Brain and nerve = Shinkei kenkyu no shinpo·2026
Same journal

[Disaster Countermeasures for Intractable Neurological Disease].

Brain and nerve = Shinkei kenkyu no shinpo·2026
Same journal

[Supporting Health Care Transition for Patients with Childhood-Onset Chronic Conditions: Within Intractable Disease Care in Japan].

Brain and nerve = Shinkei kenkyu no shinpo·2026
Same journal

[Multidisciplinary Collaboration between Hospitals and Clinics at the University Hospital and the Core Hospital for the Treatment of Intractable Diseases].

Brain and nerve = Shinkei kenkyu no shinpo·2026
Same journal

[The Role of Coordinators for Intractable Diseases in Japan].

Brain and nerve = Shinkei kenkyu no shinpo·2026
See all related articles

Related Experiment Video

Updated: Jun 26, 2025

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
10:04

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging

Published on: October 20, 2017

13.4K

[AL Amyloidosis].

Mitsuharu Ueda1

  • 1Department of Neurology, Graduate School of Medical Sciences, Kumamoto University.

Brain and Nerve = Shinkei Kenkyu No Shinpo
|May 14, 2024
PubMed
Summary
This summary is machine-generated.

AL amyloidosis, a systemic disease from light chains, often causes peripheral neuropathy. Diagnosis needs tissue biopsies and typing, but therapies can improve survival and organ function.

More Related Videos

Rapid Generation of Amyloid from Native Proteins In vitro
05:48

Rapid Generation of Amyloid from Native Proteins In vitro

Published on: December 5, 2013

6.2K
Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
08:25

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Published on: April 19, 2021

3.3K

Related Experiment Videos

Last Updated: Jun 26, 2025

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
10:04

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging

Published on: October 20, 2017

13.4K
Rapid Generation of Amyloid from Native Proteins In vitro
05:48

Rapid Generation of Amyloid from Native Proteins In vitro

Published on: December 5, 2013

6.2K
Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
08:25

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Published on: April 19, 2021

3.3K

Area of Science:

  • Hematology
  • Neurology
  • Pathology

Background:

  • AL amyloidosis is a systemic disease caused by amyloidogenic immunoglobulin light chains.
  • Peripheral neuropathy affects 10%-40% of patients with systemic AL amyloidosis.
  • Accurate diagnosis is crucial for effective management.

Purpose of the Study:

  • To summarize the key aspects of AL amyloidosis, focusing on diagnosis and treatment.
  • To highlight the prevalence and impact of peripheral neuropathy in AL amyloidosis patients.

Main Methods:

  • Review of existing literature on AL amyloidosis.
  • Analysis of diagnostic criteria, including tissue biopsies and amyloid typing.
  • Examination of current disease-modifying therapies.

Main Results:

  • AL amyloidosis diagnosis requires tissue biopsies (skin, fat, GI) and amyloid typing.
  • Peripheral neuropathy is a common complication, impacting quality of life.
  • Disease-modifying therapies demonstrate efficacy in improving survival and preventing organ damage.

Conclusions:

  • Early and accurate diagnosis of AL amyloidosis is essential.
  • Management strategies focusing on disease modification can significantly improve patient outcomes.
  • Further research into novel therapeutic approaches is warranted.